Login to Your Account



NewCo News

Momenta Seizes on Sialix mAb Therapeutic Program

By Marie Powers
Staff Writer

Thursday, October 4, 2012

Sialix Inc. raised its biotech cred by inking an option agreement to license an undisclosed monoclonal antibody (mAb) therapeutic program with Momenta Pharmaceuticals Inc.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription